Business Description
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402681083
Share Class Description:
NKTR: Ordinary SharesCompare
Compare
Traded in other countries / regions
NKTR.USAITH.Germany0UNL.UKNKTR.Mexico IPO Date
1994-05-03Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.42 | |||||
| Equity-to-Asset | 0.23 | |||||
| Debt-to-Equity | 1.41 | |||||
| Debt-to-EBITDA | -0.77 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -14.42 | |||||
| Beneish M-Score | 5.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.9 | |||||
| 3-Year EBITDA Growth Rate | 16.5 | |||||
| 3-Year EPS without NRI Growth Rate | 30.5 | |||||
| 3-Year FCF Growth Rate | 17.2 | |||||
| 3-Year Book Growth Rate | -51.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 8.53 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -10.58 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.33 | |||||
| 9-Day RSI | 43 | |||||
| 14-Day RSI | 44.52 | |||||
| 6-1 Month Momentum % | 41.23 | |||||
| 12-1 Month Momentum % | 107.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.15 | |||||
| Quick Ratio | 4.9 | |||||
| Cash Ratio | 4.73 | |||||
| Days Inventory | 158.77 | |||||
| Days Sales Outstanding | 7.49 | |||||
| Days Payable | 59.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2 | |||||
| Shareholder Yield % | -6.29 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.22 | |||||
| Operating Margin % | -145.03 | |||||
| Net Margin % | -190.09 | |||||
| FCF Margin % | -188.25 | |||||
| ROE % | -127.63 | |||||
| ROA % | -42.69 | |||||
| ROIC % | -157.07 | |||||
| 3-Year ROIIC % | -72.75 | |||||
| ROC (Joel Greenblatt) % | -409.14 | |||||
| ROCE % | -42.11 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.46 | |||||
| PB Ratio | 2.7 | |||||
| Price-to-Tangible-Book | 2.72 | |||||
| EV-to-EBIT | -0.37 | |||||
| EV-to-EBITDA | -0.39 | |||||
| EV-to-Revenue | 0.6 | |||||
| EV-to-Forward-Revenue | 0.69 | |||||
| EV-to-FCF | -0.32 | |||||
| Price-to-Median-PS-Value | 0.24 | |||||
| Price-to-Net-Current-Asset-Value | 6.88 | |||||
| Price-to-Net-Cash | 29.25 | |||||
| Earnings Yield (Greenblatt) % | -270.27 | |||||
| FCF Yield % | -81.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NKTR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 93.157 | ||
| EPS (TTM) ($) | -0.9 | ||
| Beta | 0.63 | ||
| Volatility % | 75.63 | ||
| 14-Day RSI | 44.52 | ||
| 14-Day ATR ($) | 0.091688 | ||
| 20-Day SMA ($) | 1.2245 | ||
| 12-1 Month Momentum % | 107.71 | ||
| 52-Week Range ($) | 0.4126 - 1.928 | ||
| Shares Outstanding (Mil) | 184.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nektar Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nektar Therapeutics Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(NKTR)'s stock price today?
The current price of NKTR is $1.17. The 52 week high of NKTR is $1.93 and 52 week low is $0.41.
When is next earnings date of Nektar Therapeutics(NKTR)?
The next earnings date of Nektar Therapeutics(NKTR) is 2024-11-07 Est..
Does Nektar Therapeutics(NKTR) pay dividends? If so, how much?
Nektar Therapeutics(NKTR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers